Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)'s chief executive Jeremy Skillington talked to Proactive about the completion of in-licensing of a new vaccine candidate, POLB 003.
This new vaccine-in-waiting could prove decisive in the battle against melioidosis - also known as Whitmore's disease - an infectious bacterial condition that in some cases can prove fatal.